Abstract
Targeted therapy has emerged as a revolutionary approach in oncology, offering personalized and precision-based interventions that improve survival and quality of life. Unlike traditional chemotherapy, which indiscriminately attacks both healthy and cancerous cells, targeted therapies hone in on specific molecular markers involved in tumor growth and progression. This article explores the advancements, clinical applications, and future trends of targeted therapy in oncology. We analyze the roles of biomarkers, resistance mechanisms, combination regimens, and technological innovations like AI and CRISPR in guiding next-generation targeted treatments. The paper also discusses regulatory, ethical, and financial considerations shaping future clinical integration.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.